2021
DOI: 10.1101/2021.11.18.469078
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Metformin Suppresses SARS-CoV-2 in Cell Culture

Abstract: People with diabetes are reported to have a higher risk of experiencing severe COVID-19 complications. Metformin, a first-line medication for type 2 diabetes, has antiviral properties. Some studies have indicated its prognostic potential in COVID-19. Here, we report that metformin significantly inhibits SARS-CoV-2 growth in cell culture models. SARS-CoV-2 infection of gut epithelial cell line, Caco2, resulted in higher phosphorylation of AMPK. Metformin reduced viral titers in the infected cells by nearly 99%,… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 57 publications
0
2
0
Order By: Relevance
“…On the other hand, for DESeq2, see Table 6 (full list of drug repositioning is available in Additional file 8), The use of the second and third one, dexamethasone, resulted in lower 28-day mortality among those who received either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. [29], The seventh one, metformin, suppressed SARS-CoV-2 in cell culture [30]. The eighth one, etanercept, significantly decreased the risk of developing COVID-19 in patients with rheuma- toid arthritis or spondyloarthropathies [31].…”
Section: Drug Repositioningmentioning
confidence: 99%
“…On the other hand, for DESeq2, see Table 6 (full list of drug repositioning is available in Additional file 8), The use of the second and third one, dexamethasone, resulted in lower 28-day mortality among those who received either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. [29], The seventh one, metformin, suppressed SARS-CoV-2 in cell culture [30]. The eighth one, etanercept, significantly decreased the risk of developing COVID-19 in patients with rheuma- toid arthritis or spondyloarthropathies [31].…”
Section: Drug Repositioningmentioning
confidence: 99%
“…Metformin, a well-known AMPK activator and mTORC1 inhibitor, has also been reported to have therapeutic benefits in elderly COVID-19 patients at nursing homes in USA [135]. According to a recent cell model, metformin pre-treatment resulted in further phosphorylation of AMPK and caused a ten-fold reduction of SARS-CoV-2 viral titers [136]. Nevertheless, mTORC1 hyperactivation is associated to ACE2 overexpression, which is one of the mechanisms explaining the possible therapeutic benefit of mTORC1 inhibitors [137].…”
Section: Agents Targeting the Mtorc1-autophagy-pathwaymentioning
confidence: 99%